CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

PR Newswire Biotech
Original article

/C O R R E C T I O N -- Akeso, Inc./

Phase 1AK157D1Positive
AI Analysis

Summary

Akeso's AK157D1 (B7-H3 ADC) has been cleared for Phase I trial in solid tumors, adding a third differentiated ADC to the company's pipeline. This is a correction/amendment to the original news release issued on August 21, 2026.

Clinical Trial Data

Phase

Phase 1

Outcome Details

Cleared for Phase I Trial

Importance:5/10
Sentiment:
0.60
ADCPhase 1 ClearanceOncologyPipeline Expansion
Related Companies

Read the original article

Published by PR Newswire Biotech on August 25, 2026 1:15 PM

Read Original